Phase 1
Evaluation & Legal Examination
Ideas, internal or based on customer inquiries, are evaluated with focus on the economic value and technical feasibility and freedom to operate.
Synthetic Biology is the sustainable and potentially cost-efficient production of compounds through genetic engineering in microorganisms. We are building a new & superior Synthetic Biology operating system - unlocking the global impact of sustainable and cost-competitive production.
Cheaper and more efficient production
Flexible basis for the production of various compounds that is available off-the-shelf
Novel IP, leading to protection vs. competition
Responsible for oversight of company and R&D activities
7+ years experiences in R&D and technology strategy in the biopharmaceutical industry Diploma (M.Sc. Equivalent) in Chemistry
Prior Head of Investments at IONIQ Group (accompanied Synbionik right from the start)
B.Sc. Economics & Philosophy, M.Sc. in Management & Strategy
Former CEO of Novartis Consumer Health, Novartis Pharmaceuticals & ProSiebenSat.1 Board member of Bayer & Lonza Group
Former member of Bayer’s Board of Management, responsible for the Innovation Business Various roles with Bayer & Bristol-Myers Squibb
Professor for Organic Chemistry, Johannes Gutenberg University Mainz Synthesis & Structure elucidation of natural products
Scientific Director, Leibniz Institute DSMZ-German Culture Collection of Microorganisms & Cell Cultures, Expert in the field of Microbiology
Former Executive Vice President at TeamViewer, including lead of IPO Senior Manager at A.T. Kearney
Founder and chairman of IONIQ Group Serial entrepreneur and investor (e.g. finleap, Heartbeat Labs), Entrepreneur of the Year
Founder of Lieferheld.de & Book A Tiger Voted #2 European Tech Entrepreneur Former McKinsey & Company consultant